Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling
- PMID: 22251142
- DOI: 10.3109/03602532.2011.645580
Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling
Abstract
Enormous efforts toward predicting the metabolic fate of a drug have been driven by the high attrition rate in drug development. To accelerate such efforts, it is critical to elucidate the molecular mechanisms of drug recognition by drug-metabolizing enzymes. Therefore, it is not surprising that an increasing number of crystal structures have been determined (by X-ray crystallography) and numerous insightful in silico (computational) models have been established for the most important metabolic enzymes, cytochrome P450s (CYPs). In this review, we provide a detailed analysis of the available crystal structures for CYPs to reveal the structural features and protein flexibility determining substrate selectivity. The ligand-based in silico models (including pharmacophore and molecular field analysis models) are also discussed, with a focus on their ability to characterize the structural features of the substrates for various CYP isoforms.
Similar articles
-
Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling.Drug Metab Rev. 2012 Feb;44(1):1-17. doi: 10.3109/03602532.2011.645581. Drug Metab Rev. 2012. PMID: 22242930 Review.
-
Human P450s involved in drug metabolism and the use of structural modelling for understanding substrate selectivity and binding affinity.Xenobiotica. 2009 Aug;39(8):625-35. doi: 10.1080/00498250903000255. Xenobiotica. 2009. PMID: 19514836 Review.
-
Designing better drugs: predicting cytochrome P450 metabolism.Drug Discov Today. 2006 Jul;11(13-14):601-6. doi: 10.1016/j.drudis.2006.05.001. Drug Discov Today. 2006. PMID: 16793528
-
Human CYPs involved in drug metabolism: structures, substrates and binding affinities.Expert Opin Drug Metab Toxicol. 2010 Jun;6(6):661-74. doi: 10.1517/17425251003674380. Expert Opin Drug Metab Toxicol. 2010. PMID: 20402561 Review.
-
A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108.Chem Res Toxicol. 1996 Oct-Nov;9(7):1079-91. doi: 10.1021/tx960003i. Chem Res Toxicol. 1996. PMID: 8902262
Cited by
-
Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles.Int J Mol Sci. 2023 Feb 8;24(4):3383. doi: 10.3390/ijms24043383. Int J Mol Sci. 2023. PMID: 36834793 Free PMC article. Review.
-
Structural and thermodynamic basis of (+)-α-pinene binding to human cytochrome P450 2B6.J Am Chem Soc. 2013 Jul 17;135(28):10433-40. doi: 10.1021/ja403042k. Epub 2013 Jul 3. J Am Chem Soc. 2013. PMID: 23786449 Free PMC article.
-
Modeling of interactions between xenobiotics and cytochrome P450 (CYP) enzymes.Front Pharmacol. 2015 Jun 12;6:123. doi: 10.3389/fphar.2015.00123. eCollection 2015. Front Pharmacol. 2015. PMID: 26124721 Free PMC article. Review.
-
Many human pharmaceuticals are weak inhibitors of the cytochrome P450 system in rainbow trout (Oncorhynchus mykiss) liver S9 fractions.Front Toxicol. 2024 Jul 15;6:1406942. doi: 10.3389/ftox.2024.1406942. eCollection 2024. Front Toxicol. 2024. PMID: 39077557 Free PMC article.
-
Modelling three-dimensional protein structures for applications in drug design.Drug Discov Today. 2014 Jul;19(7):890-7. doi: 10.1016/j.drudis.2013.10.027. Epub 2013 Nov 8. Drug Discov Today. 2014. PMID: 24216321 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical